Evidence map›Paper›PMID 24883333›Full record

ArticleJournal of immunology research2014

Anti-hnRNP B1 (RA33) autoantibodies are associated with the clinical phenotype in Russian patients with rheumatoid arthritis and systemic sclerosis.

Aleksey Maslyanskiy, Natalya Lazareva, Polina Olinek, Peter Schierack, Christian Hentschel, Juliane Cuccato, Dimitrios P Bogdanos, Sergey V Lapin, Dirk Roggenbuck

Open access · goldAbstract read
In one paragraph

Article in Journal of immunology research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 3 countries.

Aleksey MaslyanskiyDepartment of Rheumatology, Almazov Medical Research Centre, 197341 St. Petersburg, Russia.
Natalya LazarevaLaboratory of Autoimmune Diagnostics, St. Petersburg Pavlov State Medical University, 197022 St. Petersburg, Russia.
Polina OlinekEichwald Department of Therapy and Rheumatology, Mechnikov Northwestern State University, 191015 St. Petersburg, Russia.
Peter SchierackFaculty of Science, Brandenburg University of Technology Cottbus-Senftenberg, Großenhainer Straße 57, 01968 Senftenberg, Germany.
Christian HentschelR/D, Medipan GmbH, Dahlewitz, 15827 Berlin, Germany.ORCID 0000-0003-0579-202X
Juliane CuccatoR/D, Medipan GmbH, Dahlewitz, 15827 Berlin, Germany.
Dimitrios P BogdanosInstitute of Liver Studies, Division of Transplantation Immunology and Mucosal Biology, King's College London School of Medicine at King's College Hospital, London SES 9RJ, UK.
Sergey V LapinLaboratory of Autoimmune Diagnostics, St. Petersburg Pavlov State Medical University, 197022 St. Petersburg, Russia.
Dirk RoggenbuckFaculty of Science, Brandenburg University of Technology Cottbus-Senftenberg, Großenhainer Straße 57, 01968 Senftenberg, Germany ; R/D, Medipan GmbH, Dahlewitz, 15827 Berlin, Germany.ORCID 0000-0002-6861-6827
Medipan (Germany) · DEFirst Pavlov State Medical University of St. Petersburg · RUBrandenburg University of Technology Cottbus-Senftenberg · DEFederal Almazov North-West Medical Research Centre · RUKing's College London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Heterogeneous nuclear ribonucleoproteins (hnRNPs) are potent autoantigenic targets in systemic autoimmune rheumatic diseases (SARD). Loss of tolerance to the RA33 complex consisting of hnRNP A2 and its alternatively spliced variants B1 and B2 has been the interest of rheumatologists. A novel ELISA for the detection of anti-hnRNP B1 autoantibodies has been developed to investigate the prevalence thereof in 397 patients with SARD, including patients with rheumatoid arthritis (RA), spondyloarthropathy (SPA), juvenile chronic arthritis, systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and Sjögren's syndrome (SS), in comparison to 174 controls. Anti-hnRNP B1 autoantibodies were significantly more prevalent in patients with SARD than controls (47/397, 11.8% versus 2/174, 1.1%; P<0.001). In particular, anti-hnRNP B1 were found more frequently in the disease cohorts than in the controls and were present in 24/165 (14.5%) patients with RA, 6/58 (10.3%) SPA, 11/65 (16.9%) SSc, and 4/50 (8.0%) SLE. In RA patients, anti-hnRNP B1 autoantibodies correlated significantly with C-reactive protein levels and erythrocyte sedimentation rate, while in patients with SSc it was associated with features of arterial wall stiffness and presence of hypertension. Anti-hnRNP B1 autoantibodies occur in SARD and seem to be correlated with distinct clinical characteristics in patients with RA and SSc.

Indexed as

AdolescentAdultArthritis, JuvenileArthritis, RheumatoidAutoantibodiesAutoantigensBlood SedimentationCase-Control StudiesChildC-Reactive ProteinEnzyme-Linked Immunosorbent AssayFemaleHeterogeneous-Nuclear Ribonucleoprotein Group A-BHumansHypertensionLupus Erythematosus, SystemicAutoantibodiesAutoantigensC-Reactive ProteinHeterogeneous-Nuclear Ribonucleoprotein Group A-BhnRNP A2

Identifiers

PMID24883333
PMCPMC4027001
OpenAlexW2052887975

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.